| 728 |
4-diethylaminobenzaldehyde (DEAB)
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 729 |
WIN18466
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 731 |
All-trans retionic acid
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 732 |
Vitamin A
|
|
436: Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries
|
| 734 |
Clomiphene citrate (1:1)
|
-
Clomiphene citrate (1:1), CAS-RN: 50-41-9, DTXSID8020337
|
440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia
|
| 737 |
Ethyl alcohol
|
|
443: DNA damage and mutations leading to Metastatic Breast Cancer
|
| 738 |
Uranium, soluble salts
|
-
Uranium, soluble salts, CAS-RN: NOCAS, DTXSID7024374
|
447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways
|
| 739 |
welding fumes
|
|
451: Interaction with lung resident cell membrane components leads to lung cancer
|
| 740 |
Carbon black
|
-
Carbon black, CAS-RN: 1333-86-4, DTXSID7051216
|
451: Interaction with lung resident cell membrane components leads to lung cancer
|
| 741 |
DCA
|
|
335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment
|
| 742 |
DCPMU
|
|
335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment
|
| 743 |
Niclosamide ethanolamine
|
|
263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
|
| 744 |
Oxyclozanide
|
-
Oxyclozanide, CAS-RN: 2277-92-1, DTXSID50177312
|
263: Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
|
| 745 |
Fumonisin B1
|
-
Fumonisin B1, CAS-RN: 116355-83-0, DTXSID6020644
|
449: Ceramide synthase inhibition leading to neural tube defects
|
| 746 |
Vismodegib
|
-
Vismodegib, CAS-RN: 879085-55-9, DTXSID40236689
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 747 |
Toluene diisocyanate
|
-
Toluene diisocyanate, CAS-RN: 26471-62-5, DTXSID0024341
|
39: Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response
|
| 750 |
Iron nanoparticles
|
|
392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation
|
| 752 |
SANT-1
|
-
(E)-N-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenylpyrazol-4-yl)methanimine, CAS-RN: 304909-07-7, DTXSID90425965
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 753 |
SANT-2
|
-
SANT-2, CAS-RN: 329196-48-7, DTXSID40362255
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 754 |
SANT-3
|
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 755 |
SANT-4
|
|
460: Antagonism of Smoothened receptor leading to orofacial clefting
|
| 756 |
GANT61
|
-
GANT61, CAS-RN: 500579-04-4, DTXSID50329591
|
491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
|
| 757 |
GANT 58
|
|
491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
|
| 759 |
NH-375
|
|
485: Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition
|
| 760 |
Lei Gong Teng (Common Threewingnut Root)
|
|
486: Binding to the extracellular protein laminin leading to decreased cognitive function
|